These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 14707409)

  • 21. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists.
    Muir KW
    Curr Opin Pharmacol; 2006 Feb; 6(1):53-60. PubMed ID: 16359918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study Group.
    Kittner B
    Alzheimer Dis Assoc Disord; 1999; 13 Suppl 3():S166-71. PubMed ID: 10609697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Designing phase III or IV trials for vaccines: choosing between individual or cluster randomised trial designs.
    Vaucher P
    Vaccine; 2009 Mar; 27(13):1928-31. PubMed ID: 19368773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases.
    van der Lee JH; Wesseling J; Tanck MW; Offringa M
    J Clin Epidemiol; 2008 Apr; 61(4):324-30. PubMed ID: 18313556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design of randomized controlled trials.
    Stanley K
    Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
    [No Abstract]   [Full Text] [Related]  

  • 27. Neuroprotection disappointment yet aGAIN.
    Wardlaw JM; Warlow CP; Sandercock PA; Dennis MS; Lindley RI
    Lancet; 2000 Aug; 356(9229):597. PubMed ID: 10950263
    [No Abstract]   [Full Text] [Related]  

  • 28. Outcome analysis in clinical trial design for acute stroke: physicians' attitudes and choices.
    Savitz SI; Benatar M; Saver JL; Fisher M
    Cerebrovasc Dis; 2008; 26(2):156-62. PubMed ID: 18560219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxaloacetate: a novel neuroprotective for acute ischemic stroke.
    Campos F; Sobrino T; Ramos-Cabrer P; Castillo J
    Int J Biochem Cell Biol; 2012 Feb; 44(2):262-5. PubMed ID: 22085530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential designs for phase III clinical trials incorporating treatment selection.
    Stallard N; Todd S
    Stat Med; 2003 Mar; 22(5):689-703. PubMed ID: 12587100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroprotective therapy for acute ischaemic stroke: down, but not out.
    Goldstein LB
    Lancet; 2004 Feb; 363(9407):414-5. PubMed ID: 14962518
    [No Abstract]   [Full Text] [Related]  

  • 32. Sample size calculations in acute stroke trials: a systematic review of their reporting, characteristics, and relationship with outcome.
    Weaver CS; Leonardi-Bee J; Bath-Hextall FJ; Bath PM
    Stroke; 2004 May; 35(5):1216-24. PubMed ID: 15031455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The ethics of thrombolytic trials beyond 3 (or 4.5) hours: randomized controlled trials are required to change clinical practice.
    Donnan GA; Davis SM
    Stroke; 2009 Apr; 40(4):1545. PubMed ID: 19286605
    [No Abstract]   [Full Text] [Related]  

  • 34. Recruiting subjects for acute stroke trials: a meta-analysis.
    Elkins JS; Khatabi T; Fung L; Rootenberg J; Johnston SC
    Stroke; 2006 Jan; 37(1):123-8. PubMed ID: 16322489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interim analyses and sequential designs in phase III studies.
    Todd S; Whitehead A; Stallard N; Whitehead J
    Br J Clin Pharmacol; 2001 May; 51(5):394-9. PubMed ID: 11421995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles.
    Samsa GP; Matchar DB
    Stroke; 2001 Mar; 32(3):669-74. PubMed ID: 11239185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ethics and practice: alternative designs for phase III randomized clinical trials.
    Palmer CR; Rosenberger WF
    Control Clin Trials; 1999 Apr; 20(2):172-86. PubMed ID: 10227416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design.
    Muir KW
    Stroke; 2002 Jun; 33(6):1545-50. PubMed ID: 12052989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of adaptive analysis on unnecessary patient recruitment: reanalysis of the RATPAC trial.
    Sutton L; Julious SA; Goodacre SW
    Ann Emerg Med; 2012 Oct; 60(4):442-8.e1. PubMed ID: 22632776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SAINT-I worked, but the neuroprotectant is not NXY-059.
    Proctor PH; Tamborello LP
    Stroke; 2007 Oct; 38(10):e109; author reply e110. PubMed ID: 17717310
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.